Asda Stores Ltd Selects TrueCommerce to Manage its Business Transformation Initiative as It Separates from Walmart

COVENTRY, United Kingdom, June 09, 2022 (GLOBE NEWSWIRE) — TrueCommerce, a leading global cloud provider of supply chain and trading partner connectivity, integration and omnichannel solutions, announced today that Asda is now using TrueCommerce’s EDI-based supplier enablement solution to manage supplier communications.

As the third-largest supermarket chain in the UK, Asda operates over 600 retail stores. The brand also offers their products online via Asda.com, which serves 98% of UK homes. To do so, Asda is supported by 37 distribution and fulfilment centres and thousands of suppliers.

In February 2021, Asda was sold by Walmart to the Issa Brothers and TDR Capital. That sale led the company to choose a new EDI provider that would support its future as a standalone business: TrueCommerce.

“TrueCommerce was part of a comprehensive RFP process and was selected on the basis of four key factors: its ability to understand and meet the Asda capability requirements, its confidence in adhering to programme timelines, its deep knowledge and expertise, and its overall commercial competitiveness,” said Jenny Hopkins, Senior Director at Asda.

As part of the agreement, TrueCommerce will implement a supplier enablement platform catering to the needs of the over 2,000 suppliers that make up Asda’s entire supplier community, with integration into the business’s SAP ERP system. As an SAP Silver Partner, TrueCommerce’s solution offers the highest level of integration and automation with the SAP system.

The solution offered by TrueCommerce features key capabilities that will enable thousands of Asda suppliers, regardless of their size or technical maturity, to easily communicate with the retailer. In addition to supporting EDI transactions, the supplier enablement platform also includes a web-EDI portal for use by non-EDI capable vendors. TrueCommerce’s platform also includes fully managed supplier onboarding and communications management for EDI-related supplier queries.

TrueCommerce’s expertise in the market and experience in managing complex supply chain communications for enterprise-grade businesses will enable a seamless transition for Asda and its supplier community. It will encourage higher rates of adoption that will, in turn, underpin the company’s ongoing supplier communication efforts.

Jenny highlighted that, “By partnering with TrueCommerce, Asda will offer a strong, stable, fully reliable and excellently managed EDI programme to our highly valued Asda suppliers, no matter how big or small they are!”

David Grosvenor, Managing Director, TrueCommerce Europe said, “I’d like to thank Jenny and the team at Asda for their cooperation in this process. Our teams at TrueCommerce are delighted to begin working with Asda and help further strengthen their business in the UK retail landscape.”

About Asda Stores Ltd

Founded in the 1960s in Yorkshire, Asda is Britain’s third largest supermarket. Dedicated colleagues serve customers from its network of stores and online services, including supercentres, superstores, supermarkets, living stores, petrol filling stations and depots across the UK. Asda was acquired by Issa TDR from Walmart in 2020.

About TrueCommerce

TrueCommerce is the most complete way to connect your business across the supply chain, integrating everything from EDI to inventory management, to fulfilment, to digital storefronts and marketplaces. We’ve revolutionised supply chain visibility and collaboration by helping organisations make the most of their omnichannel initiatives via business P2P connectivity, order management, collaborative replenishment, intelligent fulfillment, cross-functional analytics, and product information management.

The TrueCommerce Global Commerce Network can connect businesses to over 160,000 retailers, distributors, and logistics service providers. As a fully managed services provider, we also manage new trading partner onboarding, as well as the ongoing management of partner-specific mapping, labeling changes, and communications monitoring. That’s why thousands of companies—ranging from startups to the global Fortune 100, across various industries—rely on us.

TrueCommerce: Do business in every direction

For more information, visit TrueCommerce.

Media Contact
Yegor Kuznetsov, TrueCommerce
703-209-0167
yegor.kuznetsov@truecommerce.com

Clinique d’Oncologie 16 Novembre Becomes First Site in Africa to Deploy Varian’s Ethos Therapy System for Adaptive Cancer Treatment

Innovative system from Varian incorporates artificial intelligence for the efficient delivery of personalized treatments that adapt to changes in the patient’s anatomy

DUBAI, UAE, June 9, 2022 /PRNewswire/ — Advancing the treatment for cancer patients in Morocco, Clinique d’Oncologie 16 Novembre has acquired and installed the Ethos™ therapy system – the first of its kind in Africa – from Varian, a Siemens Healthineers company.  Ethos therapy, which is uniquely powered by artificial intelligence (AI), provides cancer patients with a personalized, adaptive radiotherapy treatment within a typical 15 to 30-minute time slot.

The Clinique d'Oncologie 16 Novembre clinical team with their new Ethos™ therapy system.

Adaptive therapy customizes the patient’s treatment based on tumor and anatomical changes that occur over a multi-week course of treatment. The goal is to better target the tumor, reduce doses to healthy tissue, and improve overall outcomes.

“We are proud to be the first cancer center in Africa to offer Ethos therapy treatment,” said Dr. Mounir Bachouchi, medical oncologist and CEO at Clinique d’Oncologie 16 Novembre.  “Adaptive therapy has so many benefits for both the patient and the clinician, and Varian’s Ethos system is at the leading edge of this technology, enabling our clinical team to adapt every treatment to changes in a patient’s anatomy from day to day, potentially improving overall outcomes.”

“Every patient deserves access to the best and most personalized cancer care,” said José-Manuel Valentim, Director of Africa operations at Varian. “Clinique d’Oncologie 16 Novembre is a very forward-thinking cancer center focused on offering state-of-the-art cancer care with the most advanced technologies available.”

By providing an up-to-date view of the patient’s anatomy—and the ability to use that information to adapt the treatment— Ethos therapy provides clinicians the confidence to make more informed treatment decisions. The solution is built on Varian’s latest treatment delivery technology and provides fast imaging and treatment delivery without compromising quality.

“Adaptive therapy is the future of personalized radiation therapy, and we are excited that this center is taking on a leadership role by offering Ethos to the cancer patients of Morocco,” added Valentim. “This is a transformational moment for cancer care in Northern Africa.”

About Clinique d’Oncologie 16 Novembre 

The Clinique d’Oncologie 16 Novembre was established in Rabat, Morocco to offer integrated and comprehensive multidisciplinary care for cancer patients, ranging from screening to the most innovative treatments, with full patient support and accompanying care.  It offers personalized care, emphasizing a human approach to oncology, where close relations between patients and the medical professionals are an essential component of care.

About Varian 

At Varian, a Siemens Healthineers company, we envision a world without fear of cancer. For more than 70 years, we have developed, built, and delivered innovative cancer care technologies and solutions for our clinical partners around the globe to help them treat millions of patients each year. With an Intelligent Cancer Care approach, we are harnessing advanced technologies like artificial intelligence, machine learning, and data analytics to enhance cancer treatment and expand access to care. Our 11,000 employees across 70 locations keep the patient and our clinical partners at the center of our thinking as we power new victories in cancer care. Because, for cancer patients everywhere, their fight is our fight. For more information, visit http://www.varian.com and follow @VarianMedSys on Twitter.

Press Contact 

Meryl Ginsberg
Corporate Communications
publicrelations@varian.com

Photo – https://mma.prnewswire.com/media/1835830/The_Clinique_d_Oncologie_16_Novembre_clinical_team_with_Varian_Ethos_therapy_system.jpg

International NASH Day Highlights a Common – But Unfamiliar – Liver Disease

Global Liver Institute Convenes Communities Around the Globe Today to Reverse the Growing Trend of Fatty Liver Disease

Washington, D.C., June 08, 2022 (GLOBE NEWSWIRE) — Global Liver Institute (GLI) calls attention to NASH by leading the 5th annual International NASH Day on June 9. The number of people with this advanced liver disease is expected to double by 2030, but #NASHday aims to prevent this growth. Join the movement to #StopNASHNow by listening in as 24 expert panelists from around the globe share the latest updates about the disease or adding to the conversation on social media (#NASHday). The movement permeates the globe through many locally-organized events to educate about, screen for, and prevent NASH.

NASH (nonalcoholic steatohepatitis) is a serious, progressive condition in which too much fat accumulates on the liver, leading to its inflammation and injury. It is the severe form of NAFLD (nonalcoholic fatty liver disease). Modern lifestyle and dietary patterns have contributed to increased prevalence of NASH and NAFLD around the world, and it is becoming the most common cause of liver disease. Given its widespread impact and the possibility of prevention in most cases of this disease, NASH emerges as a global health priority.

“With over a hundred million people worldwide already who have NASH and several times more in the earlier stages, people have reason to know about this progressive condition and what they can do today to combat it,” shared Donna R. Cryer, president and CEO of GLI. “Collective action is imperative to be certain that individuals in each community, no matter their background or environment, are informed and equipped to prevent fatty liver disease. The momentum that we build together today must advance and sustain the global fight against NASH.”

If you didn’t know, then now you know! Even though NASH is common, it remains relatively unknown, leaving much work to be done to increase public awareness. This year, GLI and its partners join with the theme to #StopNASHNow: Even as therapies for NASH are being developed, there are many steps that people and their doctors can take today to prevent, reverse, or slow the progression of fatty liver disease. For the 25% of adults already affected worldwide, it is due time for this life-changing knowledge.

  • An estimated 1 in 4 adults around the world already has NAFLD.
  • As many as 1 in 20 people has NASH.
  • The prevalence of NAFLD is increasing among all global regions and among all ethnicities in parallel with diabetes and obesity.
  • NASH can progress to cirrhosis or liver cancer – which may necessitate a liver transplant.

“International NASH Day demonstrates the potential that is realized as all stakeholders in NASH come together worldwide,” said Jeff McIntyre, NASH Programs Director at GLI. “From in-person screenings in at-risk communities to educational materials in 16 languages to challenging conversations with researchers, providers, and patients – today the world joins to create meaningful solutions for patients at every stage of NAFLD and NASH.”

International NASH Day has garnered the endorsement of prominent organizations from around the globe: American Association for the Study of Liver Diseases (AASLD); Association of Black Gastroenterologists and Hepatologists (ABGH); Asociación Latinoamericana para el Estudio del Hígado (ALEH); Associazione Italiana Studio del Fegato (AISF); Asociación Mexicana de Hepatología (AMH); Asian Pacific Association for the Study of the Liver (APASL); Canadian Association for the Study of the Liver (CASL); Conference on Liver Disease in Africa (COLDA); European African Treatment Advocates Network (EATAN); European Fatty Liver Conference (EFLC); European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN); EU Patient-Centric Clinical Trial Platforms (EU-PEARL); Fondazione Epatocentro Ticino; Hepatology Society, Dhaka, Bangladesh; Hepatology Society of the Philippines (HSP); Indian National Association for the Study of the Liver (INASL); North American Society For Pediatric Gastroenterology, Hepatology & Nutrition (NASPGHAN); Sociedad Argentina de Hepatologia (SAHE);Turkish Association for the Study of the Liver (TASL); United European Gastroenterology (UEG); World Gastroenterology Organisation (WGO); and World Patients Alliance (WPA).

Get Involved

To view the expert panels throughout the day today, visit https://hopin.com/events/5th-annual-international-nash-day/registration. Panels are available in English, French, Hindi, Mandarin, and Spanish throughout the day.

For additional information on International NASH Day, visit www.international-nash-day.com.

Support the NASH Day social media campaign using hashtags #NASHday #StopNASHNow. Please direct any additional questions to NASHDay@globalliver.org.

International NASH Day and its logo are registered trademarks of Global Liver Institute.

About Global Liver Institute

Global Liver Institute (GLI) is a 501(c)3 nonprofit organization founded in the belief that liver health must take its place on the global public health agenda commensurate with the prevalence and impact of liver illness. GLI promotes innovation, encourages collaboration, and supports the scaling of optimal approaches to help eradicate liver diseases. Operating globally, GLI is committed to solving the problems that matter to liver patients and equipping advocates to improve the lives of individuals and families impacted by liver disease. Follow GLI on Twitter, Facebook, Instagram, LinkedIn, and YouTube. GLI is the global host of International NASH Day.

Global Liver Institute
nashday@globalliver.org

China COVID Jitters Flare Up as Parts of Shanghai Resume Lockdown

Shanghai and Beijing went back on fresh COVID-19 alert on Thursday after parts of China’s largest economic hub imposed new lockdown restriction and the city announced a round of mass testing for millions of residents.

The most populous district in the Chinese capital, meanwhile, announced the shutdown of entertainment venues, while news of the lockdown of Shanghai’s Minhang district, home to more than 2 million people, pulled down Chinese stocks.

Both cities had recently eased heavy COVID curbs, but the country has stuck with a “dynamic zero-COVID” policy aimed at shutting down transmission chains as soon as possible.

Shanghai residents in particular are on edge as new cases flare up after the city’s grinding two-month lockdown ended, with officials on Thursday tracing three infections to the Red Rose, a popular beauty salon in the city center that reopened when the city did on June 1.

The shop had served 502 customers from 15 of Shanghai’s 16 districts in the past eight days, a local media outlet, The Paper, reported.

“When is this ever going to end?,” a user of the Twitter-like Weibo commented on the Red Rose, which is in the trendy former French Concession area of the Xuhui district. “I just want to have a normal life.”

Authorities said a preliminary investigation found that some of the salon’s 16 employees did not undergo daily COVID testing as required, and that 90,000 people linked to Red Rose staff or customers had been tested.

While China’s infection rate is low by global standards, President Xi Jinping has doubled down on a zero-COVID policy that authorities say is needed to protect the elderly and the country’s medical system, even as other countries try to live with the coronavirus.

Shanghai’s two-month lockdown, the shuttering of many malls and venues across Beijing and movement curbs imposed in many cities in recent months have battered the Chinese economy, disrupted supply chains and slowed international trade.

Authorities have been keen to revive business and started to relax some curbs in May which helped China’s exports that month to grow at a double-digit pace, beating expectations, but residents, businesses and investors are wary. China’s blue-chip CSI300 index .CSI300 ended 1.1% lower.

“The business climate is not positive because despite the fact that the cities opened, there is still the problem of the zero-COVID policy,” Christophe Lauras, president of the French Chamber of Commerce in China, told Reuters.

“That is to say that every morning people don’t know if they’ll be locked down,” he said.

Lockdowns and tests

Shanghai’s Minhang district said it will conduct nucleic acid tests for the entire population on Saturday and ordered residents to stay home in the meantime. Six other Shanghai districts, including some of its largest, also announced a round of mass testing for the weekend.

Several local-level authorities in Shanghai, which is home to 25 million people, have also issued notices saying residents will be subject to two days of confinement and another 12 days of rigorous testing starting Thursday.

Many of the notices were in the central Xuhui district, where green fences and red wooden boards have sprung up in the past week, barricading residents in and triggering fresh public anger.

In Beijing, authorities in Chaoyang district, home to more than 3 million people, ordered entertainment venues and internet cafes to shut on Thursday, while patrons of four bars were told to identify themselves and self-isolate.

China reported 240 new coronavirus cases on June 8, of which 70 were symptomatic and 170 were asymptomatic, the National Health Commission said on Thursday.

Source: Voice of America

Teslas with Autopilot a Step Closer to Recall After Crashes

Teslas with partially automated driving systems are a step closer to being recalled after the U.S. elevated its investigation into a series of crashes with parked emergency vehicles or trucks with warning signs.

The National Highway Traffic Safety Administration said Thursday that it is upgrading the Tesla probe to an engineering analysis, a sign of increased scrutiny of the electric vehicle maker and automated systems that perform at least some driving tasks.

Documents posted Thursday by the agency raise some serious issues about Tesla’s Autopilot system. The agency found that it’s being used in areas where its capabilities are limited, and that many drivers aren’t taking action to avoid crashes despite warnings from the vehicle.

The probe now covers 830,000 vehicles, almost everything that the Austin, Texas, carmaker has sold in the U.S. since the start of the 2014 model year.

NHTSA reported that it has found 16 crashes into emergency vehicles and trucks with warning signs, causing 15 injuries and one death.

Investigators will evaluate additional data, vehicle performance and “explore the degree to which Autopilot and associated Tesla systems may exacerbate human factors or behavioral safety risks, undermining the effectiveness of the driver’s supervision,” the agency said.

A message was left Thursday seeking comment from Tesla.

tesla

An engineering analysis is the final stage of an investigation, and in most cases the NHTSA decides within a year if there should be a recall or if the probe should be closed.

In the majority of the 16 crashes, the Teslas issued collision alerts to the drivers just before impact. Automatic emergency braking intervened to at least slow the cars in about half the cases. On average, Autopilot gave up control of the Teslas less than a second before the crash, NHTSA said in documents detailing the probe.

NHTSA also said it’s looking into crashes involving similar patterns that did not include emergency vehicles or trucks with warning signs.

The agency found that in many cases, drivers had their hands on the steering wheel as Tesla requires, yet they failed to take action to avoid a crash. This suggests that drivers are complying with Tesla’s monitoring system, but it doesn’t make sure they’re paying attention.

In crashes were video is available, drivers should have seen first responder vehicles an average of eight seconds before impact, the agency wrote.

The agency will have to decide if there is a safety defect with Autopilot before pursuing a recall.

Investigators also wrote that a driver’s use or misuse of the driver monitoring system “or operation of a vehicle in an unintended manner does not necessarily preclude a system defect.”

The agency document all but says Tesla’s method of making sure drivers pay attention isn’t good enough, and that it’s defective and should be recalled, said Bryant Walker Smith, a University of South Carolina law professor who studies automated vehicles.

“It is really easy to have a hand on the wheel and be completely disengaged from driving,” he said. Monitoring a driver’s hand position is not effective because it only measures a physical position. “It is not concerned with their mental capacity, their engagement or their ability to respond,” he said.

Similar systems from other companies such as General Motors’ Super Cruise use infrared cameras to watch a driver’s eyes or face to ensure they’re looking forward. But even these may still allow a driver to zone out, Walker Smith said.

In total, the agency looked at 191 crashes but removed 85 of them because other drivers were involved or there wasn’t enough information to do a definite assessment. Of the remaining 106, the main cause of about one-quarter of the crashes appears to be running Autopilot in areas where it has limitations, or in conditions that can interfere with its operations.

Other automakers limit use of their systems to limited-access divided highways.

In a statement, NHTSA said there aren’t any vehicles available for purchase today that can drive themselves.

“Every available vehicle requires the human driver to be in control at all times, and all state laws hold the human driver responsible for operation of their vehicles,” the agency said.

Driver-assist systems can help avoid crashes but must be used correctly and responsibly, the agency said.

Tesla did an online update of Autopilot software last fall to improve camera detection of emergency vehicle lights in low-light conditions. NHTSA has asked why the company didn’t do a recall.

NHTSA began its inquiry in August of last year after a string of crashes since 2018 in which Teslas using the company’s Autopilot or Traffic Aware Cruise Control systems hit vehicles at scenes where first responders used flashing lights, flares, an illuminated arrow board, or cones warning of hazards.

Source: Voice of America

New Vaccine May be Option for Troops with Religious Concerns

A COVID-19 vaccine that could soon win federal approval may offer a boost for the U.S. military: an opportunity to get shots into some of the thousands of service members who have refused other coronavirus vaccines for religious reasons.

At least 175 active duty and reserve service members have already received the Novavax vaccine, some even traveling overseas at their own expense to get it. The vaccine meets Defense Department requirements because it has the World Health Organization’s emergency use approval and is used in Europe and other regions. The Food and Drug Administration is considering giving it emergency use authorization in the U.S.

The Novavax vaccine may be an acceptable option for some of the 27,000 service members who have sought religious exemptions from the mandatory vaccine. Military officials say many troops who refuse the shots cite certain COVID-19 vaccines’ remote connection to abortions.

Laboratory-grown cell lines descended from fetuses that were aborted decades ago were used in some early-stage testing of the Pfizer and Moderna vaccines and to grow viruses used to manufacture the Johnson & Johnson vaccine. The vaccines do not contain fetal cells.

Novavax, however, says that ”no human fetal-derived cell lines or tissue” were used in the development, manufacture or production of its vaccine.

Defense Secretary Lloyd Austin made COVID-19 vaccinations mandatory last year, saying the shots were critical to maintaining military readiness and the health of the force. Military leaders have argued that troops for decades have been required to get as many as 17 vaccines, particularly for those who are deploying overseas.

One group involved in lawsuits targeting the military’s vaccine requirement said it’s possible some shot opponents may see Novavax as an amenable option.

“I definitely think it is for some, but certainly not for all,” said Mike Berry, director of military affairs for First Liberty Institute. “There are some for whom abortion is really the ultimate issue, and once that issue is resolved for them spiritually, then they’re willing.”

Berry added, however, that for others, abortion is “just a tangential issue,” and they have broader opposition to vaccines as a whole. “A rudimentary way of looking at it is that they’ve asked for God’s will, and they believe that it would be wrong for them to get the vaccine,” Berry said. “In other words, they believe that God has told them no.”

Novavax also may appeal to people who are uncomfortable with the new genetic-based technology used in Pfizer and Moderna’s so-called mRNA vaccines. They deliver genetic instructions for the body to make copies of the coronavirus’ outer coating, the spike protein.

The Novavax vaccine is made with a more familiar technology, like those used for years to prevent hepatitis B and shingles. It trains the body to fight the coronavirus by delivering copies of the outer coating which are grown in insect cells, then are purified and packaged into nanoparticles that to the immune system resemble a virus, according to Novavax research chief Dr. Gregory Glenn.

While some religious groups oppose the shots, when COVID-19 vaccines first started rolling out the Vatican’s doctrine office called the options “morally acceptable” and Pope Francis, who has received Pfizer shots, has strongly encouraged widespread vaccination.

Berry said he doesn’t know how many would consider Novavax acceptable, but guessed it may be a small percentage. First Liberty Institute and the law firm Schaerr Jaffe LLP are representing a number of Navy sailors in one lawsuit, and nine airmen in another.

Military officials declined to publicly detail the nature of any service members’ religious exemption requests, but spoke on condition of anonymity to provide some descriptions. They said that the most predominant issue mentioned in waiver requests is the remote link to fetal cell lines, while others argue that their body is a temple that must remain pure. Others, officials said, describe reasons that appear to have less connection to faith.

Berry said his firm carefully screens individuals for the lawsuits, to make sure their objections are based on sincerely held religious beliefs, rather than political or other opposition masquerading as faith-based views.

The military can’t administer the Novavax shot now, and won’t pay for anyone’s travel overseas to get it. But tens of thousands of American forces are based in Europe, where Novavax is available.

Earlier this week, advisers to the FDA backed the Novavax vaccine. Next, the FDA must decide whether to authorize it. A final FDA decision isn’t expected immediately, as the agency finishes combing through the data.

Across the military, more than 5,000 service members have been discharged for refusing the vaccine, according to the latest statistics provided by the services. Of those who requested religious exemptions, only slightly more than 100 have been approved.

In the lawsuit against the Navy, a federal judge in Texas agreed the case can go forward as a class-action lawsuit and issued a preliminary injunction barring the service from taking action against sailors who objected to the vaccine on religious grounds. Berry said the Justice Department has said it will appeal the ruling to the 5th Circuit Court of Appeals.

In the Air Force lawsuit, Berry said, lawyers have asked that it also be a class action, and they are seeking a temporary restraining order preventing the Air Force from taking any adverse actions. The court has not yet ruled.

Source: Voice of America